The efficacy and safety of mizoribine in living donor kidney transplantation: a 24-week, open-label, prospective study (phase III clinical trial)

Transplantation Proceedings ◽

10.1016/s0041-1345(01)02383-1 ◽

2001 ◽

Vol 33 (7-8) ◽

pp. 3256-3258 ◽

Author(s):

D.K. Cho ◽

J.H. Kim ◽

S.H. Park ◽

J.C. Kim ◽

C.D. Kim ◽

...

Keyword(s):

Clinical Trial ◽

Living Donor ◽

Phase Iii ◽

Study Phase ◽

Efficacy And Safety ◽

Donor Kidney ◽

Phase Iii Clinical Trial ◽

Donor Kidney Transplantation ◽

Living Donor Kidney

Download Full-text

Mizoribine in Living Donor Kidney Transplantation: Twenty four-week Results of A Single Center, Pre-randomized, Open-label, Prospective, Comparative, Phase III Study*

Transplantation Journal ◽

10.1097/00007890-199904150-00617 ◽

1999 ◽

Vol 67 (7) ◽

pp. S154

Author(s):

D. K. Cho ◽

S. H. Park ◽

J. C. Kim ◽

C. D. Kim ◽

M. Y. Baek ◽

...

Keyword(s):

Kidney Transplantation ◽

Living Donor ◽

Phase Iii ◽

Single Center ◽

Donor Kidney ◽

Living Donor Kidney Transplantation ◽

Phase Iii Study ◽

Donor Kidney Transplantation ◽

Living Donor Kidney

Download Full-text

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.13922 ◽

2019 ◽

Vol 22 (4) ◽

pp. 540-548 ◽

Author(s):

Eiichi Araki ◽

Hirotaka Watada ◽

Yasuko Uchigata ◽

Osamu Tomonaga ◽

Hitomi Fujii ◽

...

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v1/review3 ◽

2019 ◽

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text

Decision letter for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v1/decision1 ◽

2019 ◽

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text

A Phase-I Clinical Trial of Donor-Derived MIC Cell Infusion for the Induction of Donor-Specific Hyporesponsiveness after Living Donor Kidney Transplantation (TOL-1 study)

Transplantation Journal ◽

10.1097/01.tp.0000542867.61773.39 ◽

2018 ◽

Vol 102 ◽

pp. S210

Author(s):

Christian Morath ◽

Anita Schmitt ◽

Christian Kleist ◽

Volker Daniel ◽

Gerhard Opelz ◽

...

Keyword(s):

Clinical Trial ◽

Kidney Transplantation ◽

Phase I ◽

Living Donor ◽

Phase I Clinical Trial ◽

Donor Kidney ◽

Living Donor Kidney Transplantation ◽

Donor Kidney Transplantation ◽

Living Donor Kidney

Download Full-text

SaO011A PHASE-I CLINICAL TRIAL OF DONOR-DERIVED MIC CELL INFUSION FOR THE INDUCTION OF DONOR-SPECIFIC HYPORESPONSIVENESS AFTER LIVING DONOR KIDNEY TRANSPLANTATION (TOL-1 STUDY)

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfy104.sao011 ◽

2018 ◽

Vol 33 (suppl_1) ◽

pp. i320-i320

Author(s):

Christian Morath ◽

Anita Schmitt ◽

Christian Kleist ◽

Volker Daniel ◽

Gerhard Opelz ◽

...

Keyword(s):

Clinical Trial ◽

Kidney Transplantation ◽

Phase I ◽

Living Donor ◽

Phase I Clinical Trial ◽

Donor Kidney ◽

Living Donor Kidney Transplantation ◽

Donor Kidney Transplantation ◽

Living Donor Kidney

Download Full-text

Review for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v1/review2 ◽

2019 ◽

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v1/review1 ◽

2019 ◽

Author(s):

Torben Biester

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v2/review1 ◽

2019 ◽

Author(s):

Torben Biester

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text

Author response for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v2/response1 ◽

2019 ◽

Author(s):

Eiichi Araki ◽

Hirotaka Watada ◽

Yasuko Uchigata ◽

Osamu Tomonaga ◽

Hitomi Fujii ◽

...

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Author Response ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text